GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2007

Pall to Use Chembio’s Dual Path Platform Immunoassay

  • Chembio Diagnostics signed an initial R&D collaboration with Pall related to its Dual Path Platform (DPP™). The transaction is a two-phase funded feasibility study that will help ascertain performance characteristics of DPP when used in conjunction with certain markers that are of interest to Pall.

    If performance meets or exceeds certain levels, Chembio anticipates that the parties would proceed to negotiation of license, development, and manufacturing agreements related to these and potentially other markers.

    Chembio reports that the DPP immunoassay demonstrates improved detectability, sensitivity, and specificity compared to single path lateral flow (SPLF) tests. It is a lateral flow technology that employs separate membrane strips for sample migration and test reagents. It allows for complete control and management of the sample flow, hence the immunological reaction is much more efficient than conventional SPLF tests, according to Chembio.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »